Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bio Trim settlement

This article was originally published in The Tan Sheet

Executive Summary

The marketers of glucomannan-based Bio Trim are "permanently prohibited" from making false and misleading claims about weight-loss products, FTC announces Nov. 7. A suspended judgment totaling more than $2.1 mil. in consumer injury will be due immediately if either Natural Products, Natural 4 U or their owner Ana Solkamans are found to have misrepresented their financial status. The complaint is the fifth of six "Operation Big Fat Lie" suits settled since their filing in November 2004 (1"The Tan Sheet" Nov. 15, 2005, p. 14 and 2"The Tan Sheet" August 1, 2005, p. 15)...

You may also be interested in...



FTC Targets Herbal Remedies Marketed to Hispanics, Settles “Fat Lie” Suit

Latinos Group Promotions must notify consumers and resellers of its herbal supplement Arcomig and its powdered tea Essiac Formula that claims made for the products were false and unsupported, according to a stipulated judgment announced by the Federal Trade Commission July 26

“Operation Big Fat Lie”: FTC Files Suits, Fights Bogus Weight-Loss Ads

FTC's "Red Flag" initiative has roughly halved the number of ads with fraudulent weight-loss claims since its inception, according to the commission

Boehringer Ingelheim, Gubra Enter Third Obesity Deal

The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel